International Virtual Janssen Expert Program IBD Event, Dec. 10th @16:30

Virtual Janssen Expert Program
Inflammatory Bowel Disease

Inflammatory Bowel Disease:
"the right decision for future remission"

Dear dr. Molnár,

We are pleased to invite you to the first Janssen Expert Program on Inflammatory Bowel Disease. We are going virtual this year and we will be streaming the event on-line.

Scientific agenda will be focused on treatment novelties in the context of Inflammatory Bowel Disease, keeping in mind the relevance to your clinical practice.

We sincerely hope you will be able to join us during this live event and have the opportunity to interact with the faculty during the interactive segments of the program.

REGISTER & JOIN HERE →

* Due to privacy and legal requirements, registration to participate on the virtual event is necessary.

Agenda

16.30

Introduction

prof. Željko Krznarić, MD, PhD (Croatia) - Scientific Committee

16.35

New insights in Inflammatory Bowel Disease Pathophysiology

prof. Alexander Moschen, MD, PhD (Austria)

17.05

Extraintestinal Manifestations in Inflammatory Bowel Disease

prof. Tamás Molnár, MD, PhD (Hungary)

17.20

Persistence of ustekinumab in Inflammatory Bowel disease Patients: Data Analysis

prof. Milan Lukáš, MD, PhD (Czech republic)

17.35

Does azathioprine still play a role in Ulcerative Colitis in 2020?

assist. prof. David Drobne, MD, PhD (Slovenia) - Scientific Committee

17.50

The current standpoints for the long-term management of Inflammatory Bowel Disease

assoc. prof. Zuzana Zelinková, MD, PhD (Slovakia)

18.05

Implementing recent clinical data in new dimension of Inflammatory Bowel Disease patients care

Vedran Tomašić, MD (Croatia)

18.20

Q & A Session

prof. Željko Krznarić, MD, PhD (Croatia)

DOWNLOAD AGENDA →

Kind regards,

Janssen Immunology

This communication is designed for HCPs only in Hungary.

EM-47427 (finalized on November, 2020)

Confidentiality Notice: This e-mail contains confidential or legally privilegged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient, you are hereby notified that any information that is intended only for the individual or entity named in the e-mail disclosure, copying, distribution upon the contents of this e-mail is prohibited. If you have received thie e-mail in error, please reply to the sender so that we can arrange a proper delivery, and then please delete the message from your in-box. Thank you.